183 related articles for article (PubMed ID: 33207133)
21. Incremental value of magnetic resonance imaging for clinically high risk prostate cancer in 922 radical prostatectomies.
Jeong IG; Lim JH; You D; Kim MH; Choi HJ; Kim JK; Cho KS; Hong JH; Ahn H; Kim CS
J Urol; 2013 Dec; 190(6):2054-60. PubMed ID: 23791890
[TBL] [Abstract][Full Text] [Related]
22. Multiparametric Magnetic Resonance Imaging Is an Independent Predictor of Salvage Radiotherapy Outcomes After Radical Prostatectomy.
Sharma V; Nehra A; Colicchia M; Westerman ME; Kawashima A; Froemming AT; Kwon ED; Mynderse LA; Karnes RJ
Eur Urol; 2018 Jun; 73(6):879-887. PubMed ID: 29195777
[TBL] [Abstract][Full Text] [Related]
23. Findings on Diagnostic Magnetic Resonance Imaging Before Radiotherapy for Prostate Cancer.
Dahan J; Delouya G; Lambert C; Olivié DAR; Billiard JS; Taussky D
Can Assoc Radiol J; 2023 May; 74(2):382-387. PubMed ID: 36325740
[TBL] [Abstract][Full Text] [Related]
24. Clinical, Pathological and Oncologic Findings of Radical Prostatectomy with Extraprostatic Extension Diagnosed on Preoperative Prostate Biopsy.
Faisal FA; Tosoian JJ; Han M; Macura KJ; Pavlovich CP; Lotan TL
J Urol; 2019 May; 201(5):937-942. PubMed ID: 30414957
[TBL] [Abstract][Full Text] [Related]
25. Long-Term Risk of Clinical Progression Utilizing Magnetic Resonance Imaging Findings of Locally Recurrent Prostate Cancer in Patients with Biochemical Recurrence following Radical Prostatectomy.
Tanaka T; Kawashima A; Rangel LJ; Schulte PJ; Froemming AT; King BF; Mynderse LA; Karnes RJ
J Urol; 2022 May; 207(5):1038-1047. PubMed ID: 34981952
[TBL] [Abstract][Full Text] [Related]
26. Prognostic capabilities and clinical utility of cell cycle progression testing, prostate imaging reporting and data system, version 2, and clinicopathologic data in management of localized prostate cancer.
Morris DS; Woods JS; Edwards B; Lenz L; Logan J; Flake DD; Mabey B; Bishoff JT; Cohen T; Stone S
Urol Oncol; 2021 Jun; 39(6):366.e19-366.e28. PubMed ID: 33257218
[TBL] [Abstract][Full Text] [Related]
27. A novel imaging based Nomogram for predicting post-surgical biochemical recurrence and adverse pathology of prostate cancer from pre-operative bi-parametric MRI.
Li L; Shiradkar R; Leo P; Algohary A; Fu P; Tirumani SH; Mahran A; Buzzy C; Obmann VC; Mansoori B; El-Fahmawi A; Shahait M; Tewari A; Magi-Galluzzi C; Lee D; Lal P; Ponsky L; Klein E; Purysko AS; Madabhushi A
EBioMedicine; 2021 Jan; 63():103163. PubMed ID: 33321450
[TBL] [Abstract][Full Text] [Related]
28. Clinical Findings and Treatment Outcomes in Patients with Extraprostatic Extension Identified on Prostate Biopsy.
Fleshner K; Assel M; Benfante N; Lee J; Vickers A; Fine S; Carlsson S; Eastham J
J Urol; 2016 Sep; 196(3):703-8. PubMed ID: 27049874
[TBL] [Abstract][Full Text] [Related]
29. The Long-Term Risks of Metastases in Men on Active Surveillance for Early Stage Prostate Cancer.
Maggi M; Cowan JE; Fasulo V; Washington SL; Lonergan PE; Sciarra A; Nguyen HG; Carroll PR
J Urol; 2020 Dec; 204(6):1222-1228. PubMed ID: 33157570
[TBL] [Abstract][Full Text] [Related]
30. Characteristics of Anteriorly Located Prostate Cancer and the Usefulness of Multiparametric Magnetic Resonance Imaging for Diagnosis.
Kim M; Choi SK; Park M; Shim M; Song C; Jeong IG; Hong JH; Kim CS; Ahn H
J Urol; 2016 Aug; 196(2):367-73. PubMed ID: 26997311
[TBL] [Abstract][Full Text] [Related]
31. Preoperative 3-Tesla multiparametric endorectal magnetic resonance imaging findings and the odds of upgrading and upstaging at radical prostatectomy in men with clinically localized prostate cancer.
Hegde JV; Chen MH; Mulkern RV; Fennessy FM; D'Amico AV; Tempany CM
Int J Radiat Oncol Biol Phys; 2013 Feb; 85(2):e101-7. PubMed ID: 23040223
[TBL] [Abstract][Full Text] [Related]
32. Combined Clinical Parameters and Multiparametric Magnetic Resonance Imaging for the Prediction of Extraprostatic Disease-A Risk Model for Patient-tailored Risk Stratification When Planning Radical Prostatectomy.
Nyarangi-Dix J; Wiesenfarth M; Bonekamp D; Hitthaler B; Schütz V; Dieffenbacher S; Mueller-Wolf M; Roth W; Stenzinger A; Duensing S; Roethke M; Teber D; Schlemmer HP; Hohenfellner M; Radtke JP
Eur Urol Focus; 2020 Nov; 6(6):1205-1212. PubMed ID: 30477971
[TBL] [Abstract][Full Text] [Related]
33. EAU guidelines on prostate cancer. part 1: screening, diagnosis, and local treatment with curative intent-update 2013.
Heidenreich A; Bastian PJ; Bellmunt J; Bolla M; Joniau S; van der Kwast T; Mason M; Matveev V; Wiegel T; Zattoni F; Mottet N;
Eur Urol; 2014 Jan; 65(1):124-37. PubMed ID: 24207135
[TBL] [Abstract][Full Text] [Related]
34. Pretreatment 3T multiparametric MRI staging predicts for biochemical failure in high-risk prostate cancer treated with combination high-dose-rate brachytherapy and external beam radiotherapy.
Hegde JV; Demanes DJ; Veruttipong D; Raince J; Park SJ; Raman SS; Nickols NG; King CR; Kishan AU; Steinberg ML; Kamrava M
Brachytherapy; 2017; 16(6):1106-1112. PubMed ID: 28807747
[TBL] [Abstract][Full Text] [Related]
35. Risk assessment of metastatic recurrence in patients with prostate cancer by using the Cancer of the Prostate Risk Assessment score: results from 2937 European patients.
Budäus L; Isbarn H; Tennstedt P; Salomon G; Schlomm T; Steuber T; Haese A; Chun F; Fisch M; Michl U; Heinzer H; Huland H; Graefen M
BJU Int; 2012 Dec; 110(11):1714-20. PubMed ID: 22520619
[TBL] [Abstract][Full Text] [Related]
36. Triggers and oncologic outcome of salvage radical prostatectomy, salvage radiotherapy and active surveillance after focal therapy of prostate cancer.
von Hardenberg J; Cash H; Koch D; Borkowetz A; Bruendl J; Leyh-Bannurah SR; Kuru TH; Kowalewski KF; Schindele D; Mala KS; Westhoff N; Blana A; Schostak M;
World J Urol; 2021 Oct; 39(10):3747-3754. PubMed ID: 33881557
[TBL] [Abstract][Full Text] [Related]
37. Does the Visibility of Grade Group 1 Prostate Cancer on Baseline Multiparametric Magnetic Resonance Imaging Impact Clinical Outcomes?
Deniffel D; Salinas E; Ientilucci M; Evans AJ; Fleshner N; Ghai S; Hamilton R; Roberts A; Toi A; van der Kwast T; Zlotta A; Finelli A; Haider MA; Perlis N
J Urol; 2020 Dec; 204(6):1187-1194. PubMed ID: 32496160
[TBL] [Abstract][Full Text] [Related]
38. Accuracy of preoperative multiparametric magnetic resonance imaging for prediction of unfavorable pathology in patients with localized prostate cancer undergoing radical prostatectomy.
Lee H; Kim CK; Park BK; Sung HH; Han DH; Jeon HG; Jeong BC; Seo SI; Jeon SS; Choi HY; Lee HM
World J Urol; 2017 Jun; 35(6):929-934. PubMed ID: 27738805
[TBL] [Abstract][Full Text] [Related]
39. Low PI-RADS assessment category excludes extraprostatic extension (≥pT3a) of prostate cancer: a histology-validated study including 301 operated patients.
Alessi S; Pricolo P; Summers P; Femia M; Tagliabue E; Renne G; Bianchi R; Musi G; De Cobelli O; Jereczek-Fossa BA; Bellomi M; Petralia G
Eur Radiol; 2019 Oct; 29(10):5478-5487. PubMed ID: 30887199
[TBL] [Abstract][Full Text] [Related]
40. A multivariable analysis of clinical factors predicting for pathological features associated with local failure after radical prostatectomy for prostate cancer.
D'Amico AV; Whittington R; Malkowicz SB; Schnall M; Tomaszewski J; Schultz D; Kao G; VanArsdalen K; Wein A
Int J Radiat Oncol Biol Phys; 1994 Sep; 30(2):293-302. PubMed ID: 7928457
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
